EHA2025レポート⑥ 注目演題

再発・難治性多発性骨髄腫に新たな三重特異性抗体
―第Ⅰ相試験中間報告 FIRST-IN-HUMAN STUDY OF JNJ-79635322 (JNJ-5322), A NOVEL, NEXT-GENERATION TRISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL PHASE 1 RESULTS (#S100)

Rakesh Popat（National Institute for Health Research University College London Hospitals NHS Foundation Trust, United Kingdom）